BHVN NYSE
Credit Risk of going bust: higher than 78% of companies Debt: 11.4% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.33 (down 98%), Biohaven Ltd. would be worth roughly what it owes.
Total debt $297.0M against a stock market value of $2.31B.
Distance to default 2.74 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $134.4M (short-term plus half of long-term), stock volatility 96.9%; Altman Z'' -27.13. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
New Haven, CT 06510
US
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Gentile Kimberly | A-Award | 1,000 | $12.34 | 2026-09-15 |
| Yetimoglu John | 0 | — | 2026-08-06 | |
| Volles Warren Karl | 0 | — | 2026-07-09 | |
| Volles Warren Karl | 300,000 | $7.00 | 2026-07-09 | |
| Volles Warren Karl | 78,750 | $29.49 | 2026-07-09 |